Ashish Kacholia Portfolio Stock: This small-cap bags approval to market its blockbuster generic drug in Spain!

The stock is up by 45 per cent in 6 months and generated multibagger returns of over 300 per cent in just 3 years.

Venus Remedies Limited, a leading research-based global pharmaceutical company, has achieved yet another landmark by securing marketing authorisation from Spain for meropenem, its highest-selling generic product. The company which has got this approval through its German subsidiary Venus Pharma GmbH for 500mg, 1g and 2g injections of this last-recourse antibiotic, happens to be the largest exporter of meropenem from India in the last three years.

Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd said, “With plans to launch the product in December this year, we will be able to capture a 10 per cent share in the USD 6.34 million meropenem market of Spain. The marketing approval for this critically important antibiotic has once again proved the company's world-class manufacturing capabilities and its expertise in developing high-quality products. It will help us strengthen our position in the European market as well”

Meropenem, a vital antibiotic for life-threatening infections, contributes 40 per cent to total sales. Venus Remedies launched it successfully in major European markets, securing 120+ marketing authorizations in countries like UK, France, Germany, UAE, and Australia. European market size: USD 70.34 million.

On Friday, shares of Venus Remedies Ltd gained 0.86 per cent to Rs 251 per share with an intraday high of Rs 261 and an intraday low of Rs 248.85. On June 22, the stock hit 5 per cent upper circuit to Rs 248.85 per share.

Ashish Kacholia, an ace investor owns stakes in this company. The stock is up by 45 per cent in 6 months and generated multibagger returns of over 300 per cent in just 3 years. Investors should keep an eye on this stock.